| 8.05 0 (0%) | 08-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Vigil Neuroscience, Inc., founded in 2020 and headquartered in Cambridge, Massachusetts, is a biotechnology company concentrating on microglia to develop transformative treatments for neurodegenerative diseases. The firm aims to provide disease-altering therapies for patients, their families, and caregivers affected by both rare and widespread neurological disorders. The company's primary experimental therapy is VGL101, a fully human monoclonal antibody (mAb). This compound is engineered to activate the triggering receptor expressed on myeloid cells 2 (TREM2) and is currently in Phase I clinical trials. VGL101 is being investigated for its potential in treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), cerebral adrenoleukodystrophy, and Alzheimer's disease. Furthermore, Vigil Neuroscience is also advancing an orally administered small molecule designed to act as a TREM2 agonist. This alternative therapeutic approach targets common neurodegenerative conditions associated with impaired microglial function.
Thu, 05 Jun 2025
Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact (VIGL) - Seeking Alpha
Wed, 04 Jun 2025
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP - GlobeNewswire
Wed, 21 May 2025
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi - GlobeNewswire
Thu, 23 Jan 2025
Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments - Seeking Alpha
Tue, 03 Dec 2024
Vigil Neuroscience: Down On A Competitor's Failure (NASDAQ:VIGL) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|